Karzai, Fatima VanderWeele, David Madan, Ravi Owens, Helen Cordes, Lisa Hankin, Amy Couvillon, Anna Nichols, Erin Bilusic, Marijo Beshiri, Michael Kelly, Kathleen Krishnasamy, Venkatesh Lee, Sunmin Lee, Min-Jung Yuno, Akira Trepel, Jane Merino, Maria Dittamore, Ryan MartĂŠ, Jennifer Donahue, Renee Schlom, Jeffrey Killian, Keith Meltzer, Paul Steinberg, Seth Gulley, James Lee, Jung-Min Dahut, William Additional file 2: of Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations A. Immunophenotyping of myeloid-derived suppressor cells (MDSCs). B. Statistical analysis of pharmacodynamic endpoints. (DOCX 18 kb) Durvalumab;Olaparib;mCRPC;Abiraterone;Enzalutamide;Immunotherapy;Anti-PD-L1;PARP inhibitor 2018-12-04
    https://springernature.figshare.com/articles/journal_contribution/Additional_file_2_of_Activity_of_durvalumab_plus_olaparib_in_metastatic_castration-resistant_prostate_cancer_in_men_with_and_without_DNA_damage_repair_mutations/7422335
10.6084/m9.figshare.7422335.v1